Medicine

Lessons coming from an unfavorable genetics treatment trial for Duchenne muscular dystrophy

.Attributes Medication, Released online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA confirmation after an unfavorable trial, which highlights the many complexities and also obstacles of drug development within this environment.

Articles You Can Be Interested In